Leeuwenhoek officially enters Phoenix, USA and launches international layout for healthy weight loss
Leeuwenhoek, a spinoff from National Taiwan University (NTU), participated in the "Arizona Smart Healthcare Delegation" organized by the National Federation of Small and Medium Enterprises of the Republic of China. The delegation traveled to Phoenix, Arizona, USA, to promote international collaboration in smart healthcare and precision medicine with the Arizona state government, the Mayo Clinic, and Arizona State University. This trip was more than just a short exchange; Leeuwenhoek also announced its official establishment in Phoenix Bioscience Core (850PBC), a core medical innovation hub in Phoenix, USA, becoming the Taiwanese company representing "Healthy Weight Loss" at the Taiwan AI Smart Health Showcase Center.
The global GLP-1 weight loss market is growing rapidly, and Leeuwenhoek has proposed a new natural alternative.
According to the latest market analysis report, the market size of the GLP-1 drug Ozempic is estimated to reach US$24 billion in 2025 and is expected to exceed US$73 billion by 2030.1 However, these injectable drugs are expensive, have high barriers to entry, are prone to weight gain, and have potential side effects, prompting the medical community to actively seek safer, long-term natural alternatives.
Leeuwenhoek has been deeply engaged in the field of "gut microbiome and precision metabolism" for many years. Using "Biostime," a product acquired from National Taiwan University and National Taiwan University Hospital, the company modulates the intestinal flora to achieve healthy weight loss. Its core mechanism is to naturally stimulate the secretion of natural GLP-1 in the gut. In the future, it could be combined with GLP-1-like drugs like Ozempic to reduce reliance on injectable medications. The goal is to achieve healthy weight loss without regaining weight through "microbiome modulation," potentially revolutionizing the global metabolic health market.
Leeuwenhoek enters Phoenix, launching US market layout and cooperation docking
Leeuwenhoek participated in the Arizona Smart Healthcare Delegation, engaging in discussions with the Arizona government and several medical research institutions. Leeuwenhoek also officially established its presence in Phoenix Bioscience Core (850PBC), the heart of medical innovation in Phoenix.
Leeuwenhoek will use the one-year presence as a long-term display and promotion base to showcase Taiwan's innovative achievements in gut microbiome research and healthy weight loss. It will also continue to deepen cooperation with medical institutions such as Arizona State University (ASU), the Arizona Commerce Authority (ACA), and Mayo Clinic to explore potential opportunities for clinical applications and industrial investment in the United States.
Professor Cheng-Chih Hsu, Founder and CEO of Leeuwenhoek, said, "With TSMC driving Phoenix's emergence as a hub for emerging biomedical technology, we chose this moment to establish our presence in Arizona because we believe in the strategic value of Taiwanese companies. We are committed to becoming one of the first Taiwanese biotech companies to establish a presence in Arizona, and to helping drive more of Taiwan's R&D achievements internationally."
Leeuwenhoek promotes AKK's international regulatory certification, accelerating its entry into the US market
Leeuwenhoek currently possesses the world's largest library of Akkermansia (AKK) strains. AKK strains are considered key bacteria closely linked to metabolic health in European and American clinical studies and are widely used in health industries such as obesity, blood sugar regulation, and fatty liver disease.
Leeuwenhoek has officially submitted its strain to the US FDA for both NDI and GRAS approval. Once approved, AKK will be legally approved for use in dietary supplements and functional foods in the US. This not only represents a significant breakthrough in product safety and international regulations, but also signifies the official entry of Taiwan's proprietary strains into the global health industry market.
